Cited 17 times in
A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정현철 | - |
dc.date.accessioned | 2015-04-24T16:33:01Z | - |
dc.date.available | 2015-04-24T16:33:01Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/103723 | - |
dc.description.abstract | PURPOSE: This study was conducted to evaluate the safety and efficacy of S-1 and paclitaxel combination therapy for patients with advanced gastric cancer. METHODS: Eligible patients had previously untreated advanced or relapsed gastric cancer with measurable lesion(s) and an ECOG PS of 0-2. Treatment consisted of S-1 35 mg/m(2) p.o. b.i.d. on days 1-14 followed by a 7-day off plus paclitaxel 70 mg/m(2) i.v. on days 1 and 8 of a 21-day cycle. RESULTS: Fifty-six patients (M/F = 37/19) were enrolled. The median age was 59 years. The median number of cycles administered was six (range 1-18). Out of the 53 patients evaluated, there was 1 (1.9%) CR, 20 (37.7%) confirmed PRs, 5 (9.4%) unconfirmed PRs, 21 (39.6%) SDs, and 6 (11.3%) PDs. The objective tumor response was 39.6%. The median time to progression was 29 weeks. The median survival was 51 weeks. All 56 patients were assessed for treatment safety. The treatment was well tolerated with grade 3/4 neutropenia in 20%/13%, grade 3 febrile neutropenia in 7%, grade 2/3 diarrhea in 9%/4%, vomiting in 11%/0%, stomatitis in 4%/4%, and neuropathy in 4%/0% of patients. CONCLUSIONS: S-1 and paclitaxel combination treatment is an effective regimen with a favorable toxicity profile in patients with advanced gastric cancer. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/administration & dosage | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Drug Administration Schedule | - |
dc.subject.MESH | Drug Combinations | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Invasiveness | - |
dc.subject.MESH | Neoplasm Recurrence, Local/drugtherapy* | - |
dc.subject.MESH | Neoplasm Recurrence, Local/mortality | - |
dc.subject.MESH | Neoplasm Recurrence, Local/pathology | - |
dc.subject.MESH | Oxonic Acid/administration & dosage | - |
dc.subject.MESH | Oxonic Acid/adverse effects | - |
dc.subject.MESH | Oxonic Acid/therapeutic use | - |
dc.subject.MESH | Paclitaxel/administration & dosage | - |
dc.subject.MESH | Paclitaxel/adverse effects | - |
dc.subject.MESH | Paclitaxel/therapeutic use | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Stomach Neoplasms/drugtherapy* | - |
dc.subject.MESH | Stomach Neoplasms/mortality | - |
dc.subject.MESH | Stomach Neoplasms/pathology | - |
dc.subject.MESH | Tegafur/administration & dosage | - |
dc.subject.MESH | Tegafur/adverse effects | - |
dc.subject.MESH | Tegafur/therapeutic use | - |
dc.title | A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Jae Jin Lee | - |
dc.contributor.googleauthor | Si-Young Kim | - |
dc.contributor.googleauthor | Hyun-Cheol Chung | - |
dc.contributor.googleauthor | Kyung-Hee Lee | - |
dc.contributor.googleauthor | Hong-Suk Song | - |
dc.contributor.googleauthor | Won-Ki Kang | - |
dc.contributor.googleauthor | Young-Seon Hong | - |
dc.contributor.googleauthor | In-Sil Choi | - |
dc.contributor.googleauthor | Young Yeul Lee | - |
dc.contributor.googleauthor | In-Sook Woo | - |
dc.contributor.googleauthor | Jin-Hyuk Choi | - |
dc.identifier.doi | 10.1007/s00280-008-0818-3 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03773 | - |
dc.contributor.localId | A02661 | - |
dc.relation.journalcode | J00437 | - |
dc.identifier.eissn | 1432-0843 | - |
dc.identifier.pmid | 18813927 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs00280-008-0818-3 | - |
dc.subject.keyword | Advanced gastric cancer | - |
dc.subject.keyword | Chemotherapy | - |
dc.subject.keyword | First line | - |
dc.subject.keyword | Paclitaxel | - |
dc.subject.keyword | Phase II | - |
dc.subject.keyword | S-1 | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.citation.volume | 63 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1083 | - |
dc.citation.endPage | 1090 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.63(6) : 1083-1090, 2009 | - |
dc.identifier.rimsid | 36652 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.